TRML TOURMALINE BIO INC

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:

Guggenheim Securities SMID Cap Biotech Conference, New York

Fireside Chat

Wednesday, February 5, 2025, at 1:30 pm ET

A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at .

About Tourmaline Bio

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit or follow us on or .

Media Contact

Scient PR

Sarah Mishek

  

Investor Contact

Meru Advisors

Lee M. Stern



EN
27/01/2025

Underlying

TRMLTOURMALINE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TOURMALINE BIO INC

 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotec...

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: Guggenheim Securities SMID Cap Biotech Conference, New YorkFireside ChatWednesday, Februa...

January 27, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with A...

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, has jo...

January 10, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announ...

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day – Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD, PhD join Cardiovascular Scientific Advisory Board – – Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven cardiovascular disease – NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourm...

December 10, 2024 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a virtual Investor Day on December 10, 2024, beginning at 10 a.m. ET. The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular medicine specialist serving as E...

November 14, 2024 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent...

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights – On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024 – – Cash, cash equivalents and investments of ...

November 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch